IRAK4 inhibitor
Evommune abandons EVO101, a topical IRAK4 inhibitor, for atopic dermatitis
Anika Sharma
Evommune, a California-based biotech company, has made the strategic decision to discontinue its sole clinical-stage asset, EVO101, following a thorough ...
